As immunotherapies including tyrosine kinase inhibitors become more widely used for the
treatment of a variety of malignancies, it is important for prescribers and patients to …

Reversible posterior leukoencephalopathy syndrome (RPLS), also known frequently as
posterior reversible encephalopathy syndrome (PRES), is a characteristic acute neuro …

Background Diagnosis of posterior reversible encephalopathy syndrome (PRES) requires
presence of headache, seizures, impaired vision, or altered mentation accompanied by …

Abstract Both PLK1 and EEF2K are serine⁄ threonine kinases that play important roles in the
proliferation and programmed cell death of various types of cancer. They are highly …

Posterior reversible encephalopathy syndrome (PRES) is a rare but severe neurological
syndrome that may stem from the use of some medications. Although its mechanism is not …

Posterior reversible encephalopathy syndrome (PRES) is a rare clinical-radiological entity
characterised by seizures, severe headache, mental status instability and visual …

Purpose Targeted cancer therapies have been responsible for a dramatic shift in treatment
strategies for cancer, and the number of drugs, classes, and indications are continually …

Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and
trametinib treatment following immunotherapy Posterior reversible encephalopathy …

Biomarkers have improved the clinical application of numerous targeted agents used to treat
solid tumors. In melanoma, the finding that approximately 60% of tumor cells harbor specific …

Targeted therapy with a combination of serine/threonine-protein kinase B-raf (BRAF) and
mitogen-activated protein kinase kinase (MEK) inhibitors has recently become commonly …